BiomX, Inc. Annual report pursuant to Section 13 and 15(d)

Stockholders Equity (Tables)

12 Months Ended

Dec. 31, 2020

	2020		2019

Underlying value of Common Stock ($)		5.59-6.44		1.7-10
Exercise price ($)		5.59-6.44		1.7-10
Expected volatility (%)		85.0		93.1
Term of the option (years)		6.11		6.11
Risk-free interest rate (%)		0.39-0.68		2.23

	For year ended December 31, 2020
	Number of Options			Weighted average exercise price		Aggregate intrinsic value

Outstanding at the beginning of period		3,143,802		$	1.61	$	25,733
Granted		925,700			6.17
Forfeited		(108,110	)		4.66
Exercised		(391,626	)	$	0.79
Outstanding at the end of period		3,569,766		$	3.12	$	12,338
Vested at end of period		2,334,037
Weighted average remaining contractual life – years as of December 31, 2020		7.62

	For year ended December 31, 2019
	Number of Options			Weighted average exercise price		Aggregate intrinsic value

Outstanding at the beginning of period		2,571,137		$	1.34	$	1,793
Granted		784,329			2.03
Forfeited		(137,083	)		1.90
Exercised		(74,581	)		1.34
Outstanding at the end of period		3,143,802		$	1.61	$	25,733
Vested at end of period		1,482,098
Weighted average remaining contractual life – years as of December 31, 2019		7.88

Warrant

Issuance Date

Expiration Date

Exercise
Price
Per Share
(USD)

Number of
Shares of
Common Stock
Underlying
Warrants

Private Warrants issued to Yeda (see 1 below)

May 11, 2017

May 11, 2025

)

354,829

Private Warrants issued to Founders (see 2 below)

November 27, 2017

10,589

Private Placement Warrants (see 3 below)

IPO
(December 13, 2018)

December 13, 2023

11.50

2,900,000

Public Warrants (see 4 below)

IPO
(December 13, 2018)

October 28, 2024

11.50

3,500,000

6,765,418

(*)

less than $0.001.

	Year ended December 31,
	2020		2019

Research and development expenses, net		1,815		450
General and administrative		1,075		488
		2,890		938